April 2025
This quarter marked a defining moment for EicOsis. With the launch of our collaboration with The Michael J. Fox Foundation (MJFF) to develop Parkinson’s disease as an indication, we are officially stepping into a broader role as a neuroinflammation company. In this newsletter, we are excited to share the story of how EicOsis has evolved into a leading CNS therapeutics company, advancing toward the clinic with groundbreaking science.
In this newsletter:
- Industry Analysis: Shifting Investment Trends in Q1 2025
- Financial Update: Stability Amid Industry Shifts
- Our Science: From a Butterfly to PD
- Future Indications
- Our Clinical Journey Continues
- What’s next…
January 2025
2024 has been a breakout year for EicOsis. From being recognized as one of Pepperdine University’s Most Fundable Companies to wrapping up successful Phase 1 trials for our groundbreaking leading compound, we are at the forefront of tackling pain without the risks of opioids. With growing investor interest in neuroinflammation and our trailblazing advances in sEH inhibition, we’re uniquely poised to redefine pain management and neuroinflammatory therapies.
Don’t miss this moment. Explore how we’re transforming science into solutions—and why now is the perfect time to join our journey.
In this newsletter:
- Our Industry: Investment in Pharma is booming
- Our Science: Understanding more of the potential for sEH inhibitors in collaboration with the best research institutions
- Our Progress: Tolerance, Pharmacokinetic, and safety details
- Our Finance: Runway and fundraising updates
